ArticleMolecular diversity2026
Polyprenylated acylphloroglucinols from Hypericum monogynum and their reversal of multidrug resistance in MCF-7/ADR cells.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hypericum monogynum L. is a plant used in traditional Chinese medicine for treating inflammatory disorders and infectious diseases. Seven new polyprenylated acylphloroglucinols (PPAPs) and seven known PPAPs were isolated from the flowers of H. monogynum. Structurally, compound 1 features the first rearranged PPAP with a fascinating spirocyclic 5/6/6 ring system, and compound 2 is the first example of a highly modified PPAP featuring a rare 6/5/5/5-tetracyclic system. Compound 7 is the first highly degraded PPAP. Their structures were elucidated through comprehensive analysis of HRESIMS, NMR spectroscopy, and electronic circular dichroism calculations. Additionally, five PPAPs exhibited potential multidrug resistance (MDR) reversal activity in MCF-7/ADR cells with reversal fold (RF) values ranging from 9 to 56. Notably, compound 3, the strongest MDR modulator, showed a reversal effect (RF = 56) superior to the positive control verapamil (RF = 53) at an equivalent concentration. Furthermore, primary mechanistic investigation indicated that compound 10 inhibits P-gp transport function without affecting its expression. The potential recognition mechanism between compound 10 and P-gp was predicted by molecular docking.
Indexed as
Identifiers
42105142What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.